Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Cancer Chemotherapy and Pharmacology
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2008

01.05.2008 | Review

Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

verfasst von: Vincent Launay-Vacher, Jean-Baptiste Rey, Corinne Isnard-Bagnis, Gilbert Deray, Mikael Daouphars

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).
Literatur
1.
Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G; the Insuffisance Rénale et Médicaments Anticancéreux (IRMA) Study Group (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drugs management: The IRMA Study. Cancer (in press)
2.
Meijer S, Mulder NH, Sleijfer DT, de Jong PE, Sluiter WJ, Schraffordt Koops H, van der Hem GK (1982) Nephrotoxicity of cis-diamminedichloride platinum [CDDP] during remission-induction and maintenance chemotherapy of the testicular carcinoma. Cancer Chemother Pharmacol 8:27–30PubMedCrossRef
3.
Brock PR, Koliouska DE, Baratt TM, Yeomans E, Pritchard J (1991) Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118:531–534PubMedCrossRef
4.
Yuhas JM, Culo F (1980) Selective inhibition of the nephrotoxicity of cis-dichlorodiamine platinum by WR 272l without altering its antitumor properties. Cancer Treat Rep 64:57–64PubMed
5.
Borch RF, Pleasants ME (1979) Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat renal model. Proc Natl Acad Sci USA 76:6611–6614PubMedCrossRef
6.
Berry J-P, Pauwells C, Tlouzeau S, Lespinats G (1984) Effect of Selenium in combination with cis-diamminedichloroplatinum [II] in the treatment of murine fibrosarcoma. Cancer Res 44:2864–2868PubMed
7.
Citkovic E, Hayes DM, Golbey RB, Krakoff IH (1991) Cisplatin-nephrotoxicity: diethyldithiocarbomate, WR2721 or just water. J Clin Oncol 9:707–709
8.
Litterst CL, Torres IJ, Guarino AM (1977) Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP[II]. J Clin Hematol Oncol 7:169–178
9.
Safirstein R, Daye M, Miller P, Guttenplan J (1980) Renal disposition and metabolism of liganded platinum: implications to toxicity. Fed Proc 40:651A
10.
Safirstein R, Miller P, Guttenplan JB (1984) Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25:753–758PubMedCrossRef
11.
Jacobs C, Kalman SM, Tretton M, Weiner MW (1980) Renal handling of cis-diammine dichloroplatinum [II]. Cancer Treat Rep 64:1223–1226PubMed
12.
Levi J, Jacobs C, Kalman S, McTigue M, Weiner MWJ (1980) Mechanism of cis-platinum nephrotoxicity I. Effects on sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 213:545–550PubMed
13.
Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J (1987) Cisplatin nephrotoxicity insights into mechanism. Int J Androl 10:325–346PubMed
14.
Safirstein RL, Daye M, Guttenplan JB (1983) Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin. Cancer Lett 18:329–338PubMedCrossRef
15.
Bradley LJN, Yacema KJ, Lippard SJ, Essigmann JM (1993) Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum [II]. Biochemistry 32:982–988PubMedCrossRef
16.
17.
Winston JA, Safirstein R (1985) Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 249:F490–F496PubMed
18.
Hutchinson FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen G (1988) Renal salt-wasting in patients treated with cisplatin. Ann Intern Med 108:21–25
19.
Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receiving cis-diamminedichloroplatinum II. Ann Intern Med 90:929–931PubMed
20.
Schilsky RL, Barlock A, Ozols RF (1982) Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 66:1767–1769PubMed
21.
Mavichak V, Wong NLM, Quamme GA, Magil AB, Sutton RAL, Dirks JH (1985) Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 28:914–921PubMedCrossRef
22.
Swainson CP, Colls BM, Fitzharris BM (1985) Cisplatinium and distal renal tubule toxicity. N Z Med J 98:375–378PubMed
23.
Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J (1987) Cisplatin nephrotoxicity insights into mechanism. Int J Androl 10:325–346PubMedCrossRef
24.
Schor N, Ichikawa I, Rennke HG, Troy JL, Brenner BM (1981) Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney Int 19:288–292PubMedCrossRef
25.
Gordon JA, Gattone VH (1986) Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 250:F991–F998PubMed
26.
Brady HR, Kone BC, Stroniski ME, Zeidel ML, Giebisch G, Gullans SR (1990) Mitochondrial injury: an early event in cisplatin-toxicity to renal proximal tubules. Am J Physiol 258:F1181–F1187PubMed
27.
Harder HC, Rosenberg B (1970) Inhibitory effects of anti-tumor platinum compounds on DNA, RNA, and protein synthesis in mammalian cells in vitro. Int J Cancer 6:207–216PubMedCrossRef
28.
Howle JA, Gale GR (1970) cis-Dichlorodiammine platinum II persistent and selective inhibition of deoxyribonucleic acid synthesis in vitro. Biochem Pharmacol 19:2757–2762PubMedCrossRef
29.
Munchausen LL, Rahn RO (1975) Biological and chemical effects of cis-dichlorodiammineplatinum [II] on DNA. Cancer Chemother Rep 59:643–646PubMed
30.
Roberts JJ, Prascoe JM (1972) Cross linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature 235:282–284PubMedCrossRef
31.
Zwelling LA, Anderson T, Kohn KW (1979) DNA-protein and DNA interstrand cross-linking by cis- and trans platinum [II] Diamminedichloride in Ll2lO mouse leukemia cells and relation to cytotoxicity. Cancer Res 39:365–369PubMed
32.
Fraval HNA, Rawlings CJ, Roberts JJ (1978) Increased sensitivity of UV repair deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus leuteus. Mutat Res 51:12l–32
33.
Yano T, Itoh Y, Matsuo M, Kawashiri T, Egashira N, Oishi R (2007) Involvement of both tumor necrosis factor-alpha-induced necrosis and p53-mediated caspase-dependent apoptosis in nephrotoxicity of cisplatin. Apoptosis 12:1901–1909PubMedCrossRef
34.
Shino Y, Itoh Y, Kubota T, Yano T, Sendo T, Oishi R (2003) Role of poly(ADP-ribose)polymerase in cisplatin-induced injury in LLC-PK1 cells. Free Radic Biol Med 35(8):966–977PubMedCrossRef
35.
Safirstein R, Zelent AZ, Gordon R (1988) Cisplatin-nephrotoxicity: new insights into mechanisms. In: Hacker MP, Lazo JS, Tritton TR (eds) Organ directed toxicities of anticancer drugs. Martinus Nijhof, Boston, pp 172–189
36.
37.
Goldstein RS, Mayor GH (1983) Minireview: the nephrotoxicity of cisplatin. Life Sci 32:685–690PubMedCrossRef
38.
Heidemann HTH, Gerkens JF, Jackson EK, Branch RA (1985) Attenuation of cisplatin-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Naunyn Schmiedebergs Arch Pharmacol 329:201–205PubMedCrossRef
39.
Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IA (1977) High dose cisplatinium diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381PubMedCrossRef
40.
Tark JJ, Howell SB (1978) Nephrotoxicity of cisplatinium [II]-dichlorodiammine. Clin Pharmacol Ther 23:461–466
41.
Einhorn LH, Donohue J (1977) cis Diammine dichloroplatinium, uniblastine and gleomycine combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293PubMed
42.
Cvitkovic B, Spaulding J, Bethune V, Martin J, Whitemore WF (1977) Improvement of cis-dichlorodiammineplatinum therapeutic index in an animal model. Cancer 39:1357–1361PubMedCrossRef
43.
Pera MF Jr, Zook BC, Harder HC (1979) Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammine platinum [II] in rats. Cancer Res 29:1269–1278
44.
Lehane D, Winston A, Gray R, Daskal Y (1979) The effect of diuretic pretreatment on clinical morphological and ultrastructural cis-platinium induced nephrotoxicity. Int J Radiat Oncol Biol Phys 5:1393–1399PubMed
45.
Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31–35PubMed
46.
Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13–18PubMedCrossRef
47.
Salem P, Khalyl M, Jabboury K, Hashimi L (1984) cis-Diamminedichloroplatinium [II] by a 5-day continuous infusion. Cancer 53:837–840PubMedCrossRef
48.
Haas A, Anderson L, Lad T (1983) The influence of aminoglycosides on the nephrotoxicity of cis-diammine-chloroplatinium in cancer patients. J Infect Dis 147:363PubMed
49.
Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1978) Acute renal failure after cis-dichlorodiammine-platinium [II] and gentamicin-cephalotin therapies. Cancer Treat Rep 62:693
50.
Jongejan HTM, Provost AP, Molenar JC (1988) Potentiation of cis-diamminedichloroplatinium nephrotoxicity by amikacin in rats. Cancer Chemother Pharmacol 22:178–180PubMedCrossRef
51.
Bregman CL, Williams PD (1986) Comparative nephrotoxicity of carboplatin and cisplatin in combination with actinomycin. Cancer Chemother Pharmacol 18(2):117–123PubMedCrossRef
52.
Hirosawa A, Niitani H, Hayashibara K, Tsubo IE (1989) Effects of sodium thiosulfate in combination therapy of cis-dichlorodiammine platinium and vindesine. Cancer Chemother Pharmacol 23:255–258PubMedCrossRef
53.
Howell S, Pfeifle C, Wung W, Olshen R, Lucas W, Yon J, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851PubMed
54.
Levey AS, Greene T, Kusek JW et al (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:0828 abstract
55.
Cockcroft DW, Gault MH (1976) Prediction of CrCl from serum creatinine. Nephron 16:31–41PubMed
56.
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266
57.
Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67:2089–2100PubMedCrossRef
58.
Hodgkinson E, Neville-Webbe HL, Coleman RE (2006) Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) 18(9):710–718
59.
Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL (1990) Efficacity of odansetron and the role of serotonin in cisplatin induced nausea and vomiting. N Engl J Med 322(12):810–815PubMedCrossRef
Metadaten
Titel
Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care
verfasst von
Vincent Launay-Vacher
Jean-Baptiste Rey
Corinne Isnard-Bagnis
Gilbert Deray
Mikael Daouphars
Publikationsdatum
01.05.2008
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2008
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0711-0

Weitere Artikel der Ausgabe 6/2008

Cancer Chemotherapy and Pharmacology 6/2008 Zur Ausgabe

Original Article

Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin

Original Article

A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity

Original Article

Suppression of Bcl-xL expression by a novel tumor-specific RNA interference system inhibits proliferation and enhances radiosensitivity in prostatic carcinoma cells

Original Article

The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors

Original Article

Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand

Original Article

Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise